MDT Share Price | Medtronic Plc Stock Analysis & Recommendation

Q: How big is Medtronic Plc?

Market Cap: As of Jun 18, Medtronic Plc has a market capitalization of 110,516.77 million, classifying it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Medtronic Plc reported net sales of 33,537.00 million and a net profit of 4,690.00 million.Balance Sheet Snapshot: As of Apr 25, the company reported shareholder's funds of 48,024.00 million and total assets of 91,680.00 million.

Q: What does Medtronic Plc do?

Overview:Medtronic Plc is a medical technology and services company operating in the Pharmaceuticals & Biotechnology industry, with a market cap in the large-cap bracket.Financial Snapshot:Most recent Net Sales: 8,927 Million (Quarterly Results - Apr 2025) Most recent Net Profit: 1,061 Million (Quarterly Results - Apr 2025) Market cap: USD 110,516.77 Million (Large Cap)Key Metrics:P/E: 21.00 Dividend Yield: 3.34% Debt Equity: 0.41 Return on Equity: 11.03% Price to Book: 2.30Contact Details:Address: 20 On Hatch, Hatch Street Lower, DUBLIN None : 2 Tel: ['353 1 4381700', '1 763 5052692'] Website: http://www.medtronic.com/

Q: Who are in the management team of Medtronic Plc?

As of March 2022, the management team of Medtronic Plc includes Mr. Geoffrey Martha, who serves as the Executive Chairman of the Board, President, and Chief Executive Officer. Additionally, the Board of Directors features several independent directors: Mr. Richard Anderson, Mr. Craig Arnold, Mr. Scott Donnelly, Ms. Andrea Goldsmith, and Mr. Randall Hogan.

Q: Is Medtronic Plc overvalued or undervalued?

As of 19 August 2025, the valuation grade for Medtronic Plc has moved from attractive to fair, indicating a shift in its perceived value. Based on the current metrics, the company appears to be fairly valued. The key ratios include a P/E ratio of 21, an EV to EBITDA of 15.42, and a PEG ratio of 1.00, which suggest that the stock is priced in line with its earnings growth potential.In comparison to its peers, Medtronic Plc's P/E ratio of 21.47 is higher than Abbott Laboratories' 18.36 but lower than Thermo Fisher Scientific's 30.06, indicating a competitive positioning within the industry. Despite its fair valuation, Medtronic's recent stock performance shows a YTD return of 19.67%, outperforming the S&P 500's 12.22%, although it lags behind the index over longer periods, particularly with a 5Y return of -11.16% compared to the S&P 500's 96.61%.

Q: Is Medtronic Plc technically bullish or bearish?

As of 24 October 2025, the technical trend for Medtronic Plc has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance in both time frames. The daily moving averages also indicate a mildly bullish trend. However, the Dow Theory presents a mixed view with a mildly bearish signal on the weekly chart and a mildly bullish signal on the monthly chart. In terms of performance, Medtronic has underperformed the S&P 500 over the past week and month, with returns of -2.20% and -2.16% respectively, compared to the S&P 500's gains of 1.92% and 2.32%. However, year-to-date, Medtronic has outperformed the S&P 500 with a return of 17.26% versus 15.47%. Overall, the technical stance is mildly bullish, but the recent performance suggests caution.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

10.9 M

Shareholding (Jan 2026)

FII

19.92%

Held by 565 FIIs

DII

46.1%

Held by 152 DIIs

Promoter

0.08%

How big is Medtronic Plc?

22-Jun-2025

As of Jun 18, Medtronic Plc has a market capitalization of $110.52 billion, with net sales of $33.54 billion and a net profit of $4.69 billion over the latest four quarters. The company reported shareholder's funds of $48.02 billion and total assets of $91.68 billion as of Apr 25.

View full answer

What does Medtronic Plc do?

22-Jun-2025

Medtronic Plc is a large-cap medical technology and services company with recent net sales of $8.93 billion and a net profit of $1.06 billion. Key metrics include a P/E ratio of 21.00 and a dividend yield of 3.34%.

View full answer

Who are in the management team of Medtronic Plc?

22-Jun-2025

As of March 2022, Medtronic Plc's management team is led by Mr. Geoffrey Martha, who is the Executive Chairman, President, and CEO. The Board of Directors includes independent members such as Mr. Richard Anderson, Mr. Craig Arnold, Mr. Scott Donnelly, Ms. Andrea Goldsmith, and Mr. Randall Hogan.

View full answer

Is Medtronic Plc overvalued or undervalued?

20-Sep-2025

As of August 19, 2025, Medtronic Plc is fairly valued with a P/E ratio of 21, an EV to EBITDA of 15.42, and a PEG ratio of 1.00, showing competitive positioning against peers, while achieving a YTD return of 19.67%, outperforming the S&P 500's 12.22%, but underperforming over five years with a return of -11.16% compared to the S&P 500's 96.61%.

View full answer

Is Medtronic Plc technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Medtronic Plc's technical trend is mildly bullish, supported by positive MACD and moving averages, but recent performance shows underperformance against the S&P 500, suggesting caution despite year-to-date outperformance.

View full answer

Compare Medtronic Plc with Similar Stocks

Intuitive Surgical, Inc.Stryker Corp.Danaher Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Company has a low Debt to Equity ratio (avg) at times

Poor long term growth as Operating profit has grown by an annual rate 9.68% of over the last 5 years

Positive results in Jul 25

With ROCE of 9.65%, it has a attractive valuation with a 1.95 Enterprise value to Capital Employed

High Institutional Holdings at 86.93%

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 124,176 Million (Large Cap)

P/E

22.00

Industry P/E

Dividend Yield

2.92%

Debt Equity

0.43

Return on Equity

0.00%

Price to Book

0.00

Revenue and Profits:

Net Sales:

9,017 Million

(Quarterly Results - Jan 2026)

Net Profit:

1,150 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-8.31%

6 Months

-2.9%

1 Year

-3.34%

2 Years

7.29%

3 Years

17.1%

4 Years

-11.82%

5 Years

-21.96%

Medtronic Plc for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

4.91%

EBIT Growth (5y)

9.90%

EBIT to Interest (avg)

8.66

Debt to EBITDA (avg)

1.92

Net Debt to Equity (avg)

0.41

Sales to Capital Employed (avg)

3,548.69

Tax Ratio

16.65%

Dividend Payout Ratio

77.47%

Pledged Shares

Institutional Holding

88.78%

ROCE (avg)

8.75%

ROE (avg)

9.79%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.57

EV to EBIT

22.71

EV to EBITDA

15.49

EV to Capital Employed

2.10

EV to Sales

4.20

PEG Ratio

1.39

Dividend Yield

2.97%

ROCE (Latest)

9.25%

ROE (Latest)

11.60%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Sideways

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jan 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 241 Schemes (33.86%)

Foreign Institutions

Held by 565 Foreign Institutions (19.92%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jan'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jan 2026 is 8.74% vs 2.51% in Jan 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jan 2026 is -11.74% vs -2.54% in Jan 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jan'26",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9,017.00",
          "val2": "8,292.00",
          "chgp": "8.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,470.00",
          "val2": "2,407.00",
          "chgp": "2.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "181.00",
          "val2": "179.00",
          "chgp": "1.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-293.00",
          "val2": "-146.00",
          "chgp": "-100.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,150.00",
          "val2": "1,303.00",
          "chgp": "-11.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "190.90%",
          "val2": "207.80%",
          "chgp": "-1.69%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 3.62% vs 3.64% in Apr 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is 26.67% vs -2.11% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33,537.00",
          "val2": "32,364.00",
          "chgp": "3.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9,054.00",
          "val2": "8,379.00",
          "chgp": "8.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "729.00",
          "val2": "719.00",
          "chgp": "1.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-879.00",
          "val2": "-1,028.00",
          "chgp": "14.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4,692.00",
          "val2": "3,704.00",
          "chgp": "26.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "184.70%",
          "val2": "177.10%",
          "chgp": "0.76%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jan'26 - YoY

Jan'26

Jan'25

Change(%)

Net Sales

9,017.00

8,292.00

8.74%

Operating Profit (PBDIT) excl Other Income

2,470.00

2,407.00

2.62%

Interest

181.00

179.00

1.12%

Exceptional Items

-293.00

-146.00

-100.68%

Consolidate Net Profit

1,150.00

1,303.00

-11.74%

Operating Profit Margin (Excl OI)

190.90%

207.80%

-1.69%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jan 2026 is 8.74% vs 2.51% in Jan 2025

Consolidated Net Profit

YoY Growth in quarter ended Jan 2026 is -11.74% vs -2.54% in Jan 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Apr'25

Apr'25

Apr'24

Change(%)

Net Sales

33,537.00

32,364.00

3.62%

Operating Profit (PBDIT) excl Other Income

9,054.00

8,379.00

8.06%

Interest

729.00

719.00

1.39%

Exceptional Items

-879.00

-1,028.00

14.49%

Consolidate Net Profit

4,692.00

3,704.00

26.67%

Operating Profit Margin (Excl OI)

184.70%

177.10%

0.76%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Apr 2025 is 3.62% vs 3.64% in Apr 2024

Consolidated Net Profit

YoY Growth in year ended Apr 2025 is 26.67% vs -2.11% in Apr 2024

All Annual Results

Company CV

About Medtronic Plc

Medtronic Plc

Pharmaceuticals & Biotechnology

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

Company Coordinates

Company Details

20 On Hatch, Hatch Street Lower , DUBLIN None : 2

Tel: 353 1 43817001 763 5052692

http://www.medtronic.com/

Registrar Details